Table 6.
Patients’ characteristics and risk factors for overall mortality of CAPA patients.
| Variable | N | Death (%) | Survived (%) | p |
|---|---|---|---|---|
| Respiratory diseases | 7 | 6 (85.7%) | 1 (14.3%) | 0.681 |
| Smokers | 13 | 11 (84.2%) | 2 (15.4%) | 0.622 |
| Hypertension | 21 | 18 (85.7%) | 3 (14.3%) | 0.370 |
| Cardiovascular disease | 13 | 12 (92.3%) | 1 (7.7%) | 0.188 |
| Diabetes mellitus | 16 | 14 (87.5%) | 2 (12.5%) | 0.350 |
| CKD | 8 | 8 (100%) | 0 (0%) | 0.119 |
| Haematological diseases | 3 | 2 (66.7%) | 1 (33.3%) | 0.550 |
| SOT | 3 | 3 (100%) | 0 | 0.370 |
| Malignancy | 7 | 6 (85.7%) | 1 (14.3%) | 0.681 |
| Other ID | 8 | 6 (75.0%) | 2 (15.4%) | 0.697 |
| Liver cirrhosis | 1 | 0 (0.0%) | 1 (100%) | 0.613 |
| Steroids | 41 | 33 (80.5%) | 8 (19.5%) | 0.793 |
| Immunomodulatory agents | 8 | 8(100%) | 0 (0%) | 0.119 |
| Broad-spectrum ATB | 43 | 35 (81.4%) | 8 (18.6%) | 0.278 |
| Previous antifungal therapy | 10 | 8 (80%) | 2 (20%) | 1.00 |
| CT scan previous CAPA diagnosis | 20 | 15 (75.0%) | 5 (25.0%) | 0.453 |
| CT at CAPA diagnosis | 25 | 22 (88%) | 3 (12%) | 0.134 |
| Positive Aspergillus Isolation on BAL | 19 | 15 (78.9%) | 4 (21.1%) | 0.880 |
| Positive GM on BAL | 35 | 28 (80%) | 7 (20%) | 1.00 |
| Positive serum GM | 9 | 7 (77.8%) | 2 (22.2%) | 0.852 |
| Voriconazole | 11 | 8 (72.7%) | 3 (27.3%) | 0.648 |
| Isavuconazole | 10 | 9 (90%) | 1 (10%) | 0.669 |
| Amphotericin B | 7 | 6 (85.7%) | 1 (14.3%) | 0.896 |
Abbreviations: CKD: chronic kidney disease; SOT: solid organ transplantation; CT: computed tomography; CAPA: COVID-19 associated pulmonary aspergillosis; GM: galattomannann; ID: immunedepression; ATB: antibiotic; and BAL: broncho-alveolar lavage.